PFE at a glance
Ticker NYSE: PFE. Large-cap US pharmaceutical headquartered in New York with roughly $63 billion in annual revenue. Two narratives run in parallel: a sharp post-pandemic revenue reset and a $43 billion oncology bet on the Seagen acquisition closed in late 2023. The quarterly dividend sits near $0.42 per share, paid for more than 35 years running, and the yield is well above the large-cap pharma median because the price has compressed faster than the payout. At LHFX you trade PFE as a single-stock CFD on MetaTrader 5 with a 1:20 leverage ceiling, a flat $3 per side commission, STP/ECN routing, and a 14:30 to 21:00 UTC cash session Monday to Friday. No pre-market or after-hours on the CFD.
What Pfizer actually sells in 2026
Strip away the headlines and Pfizer is a portfolio of roughly 90 marketed medicines and vaccines, grouped into four therapeutic blocks: oncology, vaccines, internal medicine, and specialty (immunology, inflammation, rare disease). Oncology became the single largest block once the Seagen deal closed in December 2023, pulling four antibody-drug-conjugate franchises into the catalogue alongside the legacy Ibrance and Xtandi cancer brands.
The vaccines pillar still includes the COVID franchise (Comirnaty, co-developed with BioNTech, and the oral antiviral Paxlovid) but it is no longer the centre of gravity. Prevnar, the pneumococcal conjugate franchise, and Abrysvo, the RSV vaccine launched in 2023 for older adults and pregnant women, are both meaningful contributors and both face direct, named competition that earnings calls re-litigate every quarter.
Internal medicine is anchored by Eliquis, the anticoagulant co-promoted with Bristol-Myers Squibb. Eliquis alone has been responsible for north of $6 billion of Pfizer revenue in recent years, which is why its inclusion in the first round of Medicare drug-price negotiation under the US Inflation Reduction Act became such a heavy item on the long-term forecast page of every sell-side model.
Where the revenue comes from
Pfizer reports a single Biopharma segment, but management discloses revenue by therapeutic area on every quarterly release. The mix changes the equity story more than the headline number does.
| Therapeutic area | Revenue share | What sits inside |
|---|---|---|
| Oncology | ~30% of revenue | Ibrance, Xtandi, plus the four marketed Seagen ADCs (Adcetris, Padcev, Tukysa, Tivdak). This block is now the growth engine of the company. |
| Vaccines | ~25% of revenue | Prevnar family, Abrysvo for RSV, and the residual Comirnaty business, now sold into commercial channels rather than government contracts. |
| Internal medicine | ~20% of revenue | Eliquis is the standout. Vyndaqel for transthyretin amyloid cardiomyopathy sits here. Paxlovid is reported alongside this block in some periods. |
| Specialty care | ~15% of revenue | Immunology and inflammation (Litfulo, Cibinqo, Xeljanz), rare disease, and the gene-therapy programmes. |
| Other | Balance | Hospital and sterile-injectable contributions, contract revenue, and other smaller lines. |
The market focuses less on absolute segment dollars and more on three deltas: ex-COVID growth, oncology growth post-Seagen, and operating margin recovery as the post-pandemic cost-savings programme runs through the P&L.
What moves the PFE share price
PFE moves on a handful of recurring inputs. Most quarters cycle through the same six themes, sometimes amplified by a regulatory headline or a competitor data drop.
Quarterly Comirnaty and Paxlovid disclosure
The post-pandemic revenue reset is still being calibrated. Combined COVID revenue fell from above $56 billion in 2022 to roughly $11 billion in 2024. Each quarter the commercial run-rate gets refined and the equity reprices around it.
Seagen contribution and ADC readouts
Padcev plus pembrolizumab combinations, the broader ADC platform, and Seagen synergy realisation all sit on the same Investor-Relations page now. Positive late-stage readouts have moved PFE four to six percent intraday since the close.
Loss-of-exclusivity calendar
Ibrance, the CDK4/6 breast-cancer brand, faces a US patent cliff in 2027. Xtandi prostate-cancer patents also expire around 2027. Both are multi-billion-dollar franchises and the pipeline narrative has to plug the gap.
Inflation Reduction Act negotiations
Eliquis was named in the first cycle of CMS Medicare drug-price negotiation, with negotiated prices effective from 2026. Future selection rounds for Ibrance, Xtandi, or Vyndaqel would extend the compression.
Cost programme execution
Management announced a multi-billion-dollar net cost savings programme covering 2024 through 2027. Operating margin recovery is the lever investors are watching to defend free cash flow while top-line growth stays muted.
Vaccine competitive dynamics
Prevnar versus Merck's Capvaxive on the pneumococcal side, and Abrysvo versus GSK's Arexvy on the RSV side, are both live competitive contests with seasonal recommendation updates from the CDC ACIP committee.
Earnings cadence and how the stock reacts
PFE reports four times a year, always before the US market open, and management hosts a conference call the same morning. The timing matters because the print and the call together set the tone for the next ninety days of trading.
Q4 / full year (late January or early February)
Full-year guide for the new fiscal year, including the COVID revenue band and the Seagen contribution baseline. This is usually the highest-information print of the calendar.
Q1 (late April to early May)
First read on annual cost-savings progress. Frequently the lowest-volatility print of the year, with limited revisions to the full-year guide unless a competitor data point has shifted the picture.
Q2 (late July to early August)
Vaccine recommendation updates ahead of the autumn RSV and flu season. A mid-year guidance adjustment is common, particularly on the Comirnaty and Abrysvo lines.
Q3 (late October to early November)
Historically the highest implied-move print since it sets up the December ASH oncology conference and the January full-year update. Forward-looking commentary on the 2027 patent cliff usually surfaces here.
Implied earnings-day moves have ranged from four to seven percent in the post-2022 window. Realised moves have been wider on the upside (oncology surprise reads, cost-programme upgrades) and narrower on the downside, with one notable exception around early-2024 when a soft initial COVID-revenue guide produced a single-day drop of roughly nine percent.
When PFE trades
PFE follows the New York Stock Exchange cash session. On the LHFX CFD that translates to 14:30 to 21:00 UTC, Monday through Friday, with US market holidays removed. There is no extended-hours liquidity on the CFD product, so earnings prints released before the open or after the close create a gap into the next regular session rather than a live tradable tick. Daylight-savings shifts in March and November move the UTC window by one hour. Daily swap is debited or credited on open positions held past the LHFX server roll, and dividends are processed as a cash adjustment on the ex-date.
Cash session, Monday to Friday. This is the only window the LHFX PFE CFD trades.
Same window expressed in New York time. Daylight-savings shifts in March and November move the UTC window by one hour.
Not available on the CFD. Pre-open prints route into the next regular-session open as a gap rather than a live move.
Not available on the CFD. After-close prints route into the next regular-session open as a gap rather than a live move.
Daily swap is applied at server roll on any open position. Long and short carry can differ; check the live spec sheet for the current rates.
Earnings releases before the US open mean the print, the call, and the first hour of reaction all happen before the CFD opens for the day. Size positions to survive the resulting gap, not to the leverage cap.
Three ways to get Pfizer exposure
Most retail traders looking at PFE have three serious options: buy the share directly through a stockbroker, trade the CFD, or take indirect exposure via a sector ETF. Each one has a different cost structure and a different set of rights.
| Feature | Direct PFE share | PFE CFD at LHFX | Pharma sector ETF |
|---|---|---|---|
| Ownership of the underlying share | Yes, full economic and voting rights | No, you hold a contract referencing the price | Indirect, you own a fund unit that holds many stocks |
| Maximum leverage available | Margin from prime broker, often 2:1 | Up to 1:20 at LHFX | Margin from prime broker, often 2:1 |
| Going short | Requires stock borrow, locate fee | Direct, same commission as long | Inverse ETF or borrow required |
| Commission | Per-share or flat fee, plus exchange fees | $3 per side at LHFX | Per-share or flat fee, plus fund expense ratio |
| Dividend treatment | Paid in cash on the pay date | Passed through as a price adjustment on ex-date | Paid by the fund, usually monthly or quarterly |
| Position size flexibility | Whole or fractional shares | Lot size starts at 1 CFD = 1 share | Whole or fractional fund units |
| Minimum capital to start | Cost of one share, around $28 | $10 LHFX account minimum | Cost of one fund unit |
| Annual carry costs | None beyond custody | Daily swap on overnight positions | Fund expense ratio, often 0.10 to 0.40% |
If your plan is a multi-year buy-and-hold for the dividend stream, owning the share directly is usually the right answer. If you want the option to short, size with leverage, or trade earnings without committing the full notional, the CFD is the structure built for that.
The sector ETF is the choice when you want pharma exposure without the single-name risk that an Eliquis IRA outcome or a pipeline failure represents.
What the CFD does not give you
A PFE CFD is a price-tracking contract. It moves dollar for dollar with the underlying Pfizer share, but it sits on the LHFX balance sheet rather than in a custodian account in your name. There is no share certificate, no proxy ballot mailed to you ahead of the annual meeting in New York, and no shareholder identification number on the Pfizer registry.
On the upside, that wrapper is what makes it possible to size a position at five percent of notional rather than 100 percent, to short the share without arranging a stock borrow, and to fund the account from $10. On the downside, it means that two things move differently: you cannot vote on board candidates or executive pay packages, and the dividend appears as a cash adjustment on the ex-date rather than a cash payment on the pay date.
If a corporate action like a spin-off or a special dividend is announced, the broker has to translate that event into an equivalent cash or position adjustment on the CFD. The economic outcome is the same but the timing and the labelling on the account statement differ from what a registered shareholder would see in their brokerage account.
Trading PFE at LHFX
LHFX offers PFE as a Contract for Difference inside MetaTrader 5 with STP/ECN routing and no dealing-desk intervention. The contract tracks the NYSE-listed Pfizer share dollar for dollar. Specifications are visible inside MT5 by right-clicking PFE in Market Watch and opening Specification.
PFE on the LHFX MT5 server, matched to the NYSE-listed Pfizer Inc share.
MetaTrader 5 on Windows, Mac, web, iOS, and Android, plus the LHFX web terminal. LHFX is a direct MetaQuotes licensee so PFE sits in the same Market Watch as forex pairs, indices, and other stock CFDs.
STP/ECN routing with no dealing desk. Orders pass straight through to aggregated US equity liquidity rather than internalised against a broker book.
Up to 1:20 on PFE. The cap is the ceiling, not a recommendation. Single-name pharma can gap several percent on a pipeline readout or an IRA selection notice; experienced traders run effective leverage well below the cap.
$3 per side, $6 round-trip per standard lot, quoted as a flat fee on top of the raw spread rather than embedded inside it.
$10 to open and fund a live account. Position margin on a single PFE CFD around $28 is roughly $1.40 at the 1:20 cap.
Variable raw spread, tightest mid-session. Spreads widen around the cash open, the cash close, and scheduled releases such as earnings or ACIP recommendation updates.
Regular NYSE cash session only: 14:30 to 21:00 UTC, Monday to Friday. No pre-market or after-hours liquidity on the CFD.
Daily swap is applied at the LHFX server roll on any position held overnight. Long and short carry differ; refer to the live spec sheet for the current rate.
Worked example: 50 CFDs around an earnings print
Take a $3,000 trading account and a working assumption that PFE is changing hands near $27.40 the morning before a Q3 print. You have a directional view that guidance for the autumn vaccine season will land at the top of the consensus range, so you want to be long into the announcement. Sizing at 50 CFDs gives you $1,370 of notional. At the 1:20 leverage ceiling the initial margin requirement is $68.50, well under three percent of the account. Round-trip commission is $3 entry plus $3 exit, so $6 in fixed cost regardless of holding period. You set a hard stop at $26.85, which is $0.55 below entry. If the trade is stopped that costs $27.50 plus the $6 in commission, just under one percent of account equity. On the upside, an in-line print followed by an oncology pipeline mention on the call lifts the share to $28.60 over the next session. Closing at $28.60 produces $60 of price profit minus $6 commission, leaving $54 of realised gain. If you had held the position past the LHFX server roll, a daily swap charge would have been debited. Always size first to the stop distance and the account, then to the leverage cap.
For live spread snapshots, contract size, swap, and dividend treatment, see the PFE instrument page. For the full commission breakdown across instrument groups, see spreads and fees, and for the leverage policy by asset class see leverage.
What can go wrong
On top of normal equity-CFD risk, PFE carries several structural exposures that have produced its largest single-session moves in the last few years. Treat them as standing inputs to position sizing.
COVID revenue is not done resetting
Government contract revenue collapsed first; commercial demand is now in the year-three private-market reset. A weaker autumn vaccination season, a shorter recommended dosing interval, or a faster-than-expected fade in Paxlovid prescribing all sit inside the band of plausible outcomes and would compress the floor revenue line that consensus currently assumes.
The Seagen acquisition has to pay back
The $43 billion price tag was set at a moment of peak COVID cash flow. Slower Padcev label expansion, integration friction across the commercial organisation, or a competitive setback in the ADC space would extend the payback period and weigh on the multiple. Pipeline readouts are not always positive.
Drug price negotiation extends beyond Eliquis
Eliquis was in the first IRA negotiation cycle. If Ibrance, Xtandi, or Vyndaqel are named in later cycles, the negotiated prices flow through gross margin starting one to two years after selection. The current model assumes a defendable pricing environment that future political cycles could undermine.
Single-stock leverage cuts both ways
A 1:20 position can be wiped out by a five percent adverse move. Pfizer has produced single-day moves above seven percent on adverse pipeline data and on guidance downgrades. Treat 1:20 as a ceiling, not a default.
Liquidity narrows around news
Pre-market guidance updates from management or competitor data drops in the same therapeutic area can produce a wider opening spread and a gap through any resting stop. Stops are not guaranteed at price, only at next available price after the gap.
Risk disclosure: CFDs are complex instruments and carry a high risk of losing money rapidly because of leverage. The majority of retail accounts lose money trading CFDs. Make sure you understand how CFDs work and that you can afford to take the high risk of losing your money. Never trade with capital you cannot afford to lose.